TY - JOUR
T1 - Inflamed and non-inflamed classes of HCC
T2 - a revised immunogenomic classification
AU - Montironi, Carla
AU - Castet, Florian
AU - Haber, Philipp K.
AU - Pinyol, Roser
AU - Torres-Martin, Miguel
AU - Torrens Fontanals, Laura
AU - Mesropian, Agavni
AU - Wang, Huan
AU - Puigvehi, Marc
AU - Maeda, Miho
AU - Leow, Wei Qiang
AU - Harrod, Elizabeth
AU - Taik, Patricia
AU - Chinburen, Jigjidsuren
AU - Taivanbaatar, Erdenebileg
AU - Chinbold, Enkhbold
AU - Solé Arqués, Manel
AU - Donovan, Michael
AU - Thung, Swan
AU - Neely, Jaclyn
AU - Mazzaferro, Vincenzo
AU - Anderson, Jeffrey
AU - Roayaie, Sasan
AU - Schwartz, Myron
AU - Villanueva, Augusto
AU - Friedman, Scott L.
AU - Uzilov, Andrew
AU - Sia, Daniela
AU - Llovet, Josep M.
N1 - Funding Information:
This study was partially funded by a grant of Bristol-Myers Squibb to JML at Mount Sinai Liver Cancer Programme, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. CM is supported by a Rio Hortega grant from Instituto de Salud Carlos III (ISCIII), Fondo Social Europeo, ID code (CM19/00039). FC is supported by a AECC Clínico Junior grant, ID code (CLJUN20007CAST). PKH is supported by the fellowship grant of the German Research Foundation (DFG: HA 8754/1–1). SLF is supported by grants from the NIDDK (R01-56621,R01-128289) and US Department of Defence (CA150272P3). DS is supported by the Tisch Cancer Institute, the Dr. Franklin M. Klion Young Scientist Research Award and the PhD Scientist Innovative Research Award. JML is supported by National Cancer Institute (P30-CA196521), NIDDK (R01 DK128289), US Department of Defence (CA150272P3), European Commission/Horizon 2020 Programme (HEPCAR, Ref. 6 67 273-2), Accelerator Award (CRUK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Generalitat de Catalunya/AGAUR (SGR-1358), Plan Estratégico de Investigación e Innovación en Salud (PERIS) (SLT017/20/000206), and the Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears, Ministerio de Economia y Competitividad (MINECO) proyectos de I+D+i PID2019-105378RB-100.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022.No commercial re-use.See rights and permissions.Published by BMJ.
PY - 2022
Y1 - 2022
N2 - Objective: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class.We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.Design: We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients.Results: Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire.A 20-gene signature was able to capture ∼90% of these tumours and is associated with response to immunotherapy.Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation.CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes.Conclusion: We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours.Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described.These features may help predict immune response in HCC.
AB - Objective: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class.We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.Design: We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients.Results: Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire.A 20-gene signature was able to capture ∼90% of these tumours and is associated with response to immunotherapy.Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation.CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes.Conclusion: We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours.Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described.These features may help predict immune response in HCC.
KW - hepatocellular carcinoma
KW - immune response
KW - immunotherapy
KW - liver immunology
KW - molecular oncology
UR - http://www.scopus.com/inward/record.url?scp=85142200485&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2021-325918
DO - 10.1136/gutjnl-2021-325918
M3 - Article
C2 - 35197323
AN - SCOPUS:85142200485
SN - 0017-5749
JO - Gut
JF - Gut
M1 - 325918
ER -